Ocular Hypertension (OHT)Symptoms, Doctors, Treatments, Advances & More
Learn About Ocular Hypertension (OHT)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Ophthalmology - Wills Eye Hospital
Jonathan Myers is an Ophthalmologist practicing medicine in Philadelphia, Pennsylvania. Dr. Myers is rated as an Elite provider by MediFind in the treatment of Ocular Hypertension (OHT). He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Glaucoma, Ocular Hypertension (OHT), Pigment-Dispersion Syndrome, Trabeculectomy, and Iridectomy. Dr. Myers is board certified in Ophthalmology. Dr. Myers is currently accepting new patients.
The Johns Hopkins Hospital
Dr. Pradeep Ramulu is a glaucoma specialist and the director of the Wilmer Eye Institute glaucoma division. He specializes in caring for both routine and complex glaucomas, including glaucomas requiring repeat operations, glaucoma occurring in the context of corneal or retinal disease and glaucoma occurring in newborns and young children. The Sheila K. West Professor of Ophthalmology at the Wilmer Eye Institute, Dr. Ramulu grew up in suburban Chicago, and became interested in the eye during medical school, during which time he studied the genes and proteins of the eye with Dr. Jeremy Nathans. After pursuing a residency in ophthalmology and fellowship training in glaucoma, he joined Wilmer in 2006. Dr. Ramulu is rated as an Elite provider by MediFind in the treatment of Ocular Hypertension (OHT). He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Glaucoma, Ocular Hypertension (OHT), Cataract, Iridectomy, and Cataract Removal. Dr. Ramulu is board certified in American Board Of Ophthalmology.
The Johns Hopkins Hospital
Dr. Harry A. Quigley is the A. Edward Maumenee Professor of Ophthalmology and developed the Glaucoma Division at the Johns Hopkins Wilmer Eye Institute. He was a founding member of the American Glaucoma Society, serving for 8 years as its Secretary and was elected to 5 year terms as chief executive officer of the Association for Research in Vision and Ophthalmology (ARVO) and editor-in-chief of Investigative Ophthalmology and Visual Science. He has published over 350 peer-reviewed articles, and his reports are the most cited in the ophthalmic literature over the last 30 years (Archives of Ophthalmology, 2007). His research has improved the early diagnosis of glaucoma and has developed instruments and techniques to identify glaucoma damage better. He has participated in pioneering studies of the epidemiology, morbidity and progression rate of glaucoma and other eye disease in American, African, Asian and Hispanic populations, serving as a consultant to the World Health Organization. In the laboratory, he has demonstrated successful gene therapy to protect retinal ganglion cells from experimental glaucoma and developed glaucoma models in monkeys, rats and mice. Dr. Quigley is rated as an Elite provider by MediFind in the treatment of Ocular Hypertension (OHT). He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Glaucoma, Ocular Hypertension (OHT), Pigment-Dispersion Syndrome, Trabeculectomy, and Iridectomy. Dr. Quigley is board certified in American Board Of Ophthalmology.
Summary: The vast majority of glaucoma cases in the United States go undetected and untreated until the late stages of the disease. Open-angle glaucoma is a progressive condition that is asymptomatic in its early to moderate stages and may be amenable to screening through telemedicine-based approaches. This study is a randomized trial to evaluate whether glaucoma screening with established tests (e.g., opt...
Summary: Malformation of the lumbosacral region (spina bifida) affects the innervation of the bladder in children. The usual evolution leads to a neurological bladder with small capacity, poor compliancy and overactivity, exposing to incontinence and obstruction to the evacuation of urine. It is responsible for renal failure requiring dialysis and transplantation. Current therapeutics aim to evacuate urine...